Vaxcyte, Inc.
PCVX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001649094
In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 7 sales; 333 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $10.5B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $4.03M in total
- 7
- 13F holdersQ2 2026, −1 vs. previous quarter
- 333
- 13F valueReported value at the end of Q2 2026
- $9.71B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$766.6M
- No comparable prior period
- Free cash flow, FY2025
- -$669.3M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 14.6M
- Shares sold short
- Change
- −2.67M
- −15.4% vs. previous
- Days to cover
- 2.89
- At average daily volume
Superinvestors holding PCVX, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Vaxcyte, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vaxcyte, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)4:52 PM ET | Nov 2 | 2 days | Cowan ElviaSVP, Finance & CAO | SSale | −3.00K | $60.92 | −$182.8K | −9.7%27.9K after | 2 lots10b5-1 |
| Nov 4, 2026 (view filing)4:51 PM ET | Nov 2 | 2 days | Wassil JimEVP, Chief Scientific Ofc, COO | SSale | −2.25K | $60.90 | −$137.0K | −1.5%145.4K after | 2 lots10b5-1 |
| Oct 7, 2026 (view filing)4:08 PM ET | Oct 5 | 2 days | Wassil JimEVP, Chief Scientific Ofc, COO | SSale | −18.0K | $86.74 | −$1.56M | −11.0%145.4K after | 10b5-1 |
| Oct 7, 2026 (view filing)4:07 PM ET | Oct 5 | 2 days | Cowan ElviaSVP, Finance & CAO | SSale | −19.0K | $86.74 | −$1.65M | −40.5%27.9K after | 10b5-1 |
| Oct 2, 2026 (view filing)4:05 PM ET | Oct 1 | 1 day | Wassil JimEVP, Chief Scientific Ofc, COO | SSale | −2.25K | $56.67 | −$127.5K | −1.5%145.4K after | 2 lots10b5-1 |
| Sep 9, 2026 (view filing)5:46 PM ET | Sep 4-9 | 5 days | Wassil JimEVP, Chief Scientific Ofc, COO | SSale | −2.71K | $60.35 | −$163.9K | −1.8%145.4K after | 2 lots |
| Sep 2, 2026 (view filing)7:58 PM ET | Sep 1 | 1 day | Wassil JimCHIEF OPERATING OFFICER | SSale | −3.48K | $61.07 | −$212.4K | −2.2%155.0K after | 4 lots |
| Aug 5, 2026 (view filing)7:01 PM ET | Aug 5 | Same day | Dhaliwal Harpreet S.Chief Technical Ops Officer | SSale | −17.0K | $55.00 | −$935.1K | −18.1%76.8K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:59 PM ET | Aug 3 | 2 days | Wassil JimCHIEF OPERATING OFFICER | SSale | −2.25K | $53.86 | −$121.2K | −1.4%157.5K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)4:58 PM ET | Aug 3 | 2 days | Guggenhime AndrewPRESIDENT AND CFO | SSale | −10.0K | $53.89 | −$538.9K | −8.7%105.2K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 333 holdersThe largest institutional positions in Vaxcyte, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 20,852,907 | $1.21B | 0.05% | +4,360,046+26.4% | Added |
| Jupiter Topco LLC | 17,965,847 | $1.04B | 0.43% | +17,965,847 | New |
| T. Rowe Price Investment Management, Inc. | 12,207,450 | $709.6M | 0.47% | +81,433+0.7% | Added |
| BlackRock, Inc. | 12,068,129 | $701.5M | 0.01% | +1,096,313+10.0% | Added |
| Ra Capital Management, L.P. | 11,474,599 | $667.0M | 5.80% | 00.0% | Unchanged |
| Wellington Management Group LLP | 7,001,565 | $407.0M | 0.07% | +1,386,968+24.7% | Added |
| Vanguard Portfolio Management LLC | 6,593,551 | $383.3M | 0.02% | +314,006+5.0% | Added |
| Vanguard Capital Management LLC | 6,348,679 | $369.0M | 0.01% | +81,978+1.3% | Added |
| State Street Corp | 5,351,698 | $311.1M | 0.01% | +911,179+20.5% | Added |
| Deep Track Capital, LP | 4,300,000 | $250.0M | 3.68% | 00.0% | Unchanged |
Holders of 5% or more of PCVX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vaxcyte, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 14.40%20.8M shares | +3.00 ppfrom 11.40% | Feb 8, 202110 filings | Aug 6, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 12.10%18.0M shares | +12.00 ppfrom 0.10% | Feb 12, 202112 filings | Aug 11, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 11.60%18.1M shares | +2.00 ppfrom 9.60% | Nov 14, 20254 filings | Nov 6, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 8.90%13.0M shares | −1.00 ppfrom 9.90% | Feb 16, 20217 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.60%9.83M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
Politician trades
All politician trades in PCVX3 members of Congress reported 9 trades in Vaxcyte, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 4, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Jun 8, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Jun 8, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| May 6, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| May 6, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
House · CA · Sep 4, 2026
Buy$1K-$15K
House · CA · Jun 8, 2026
Buy$1K-$15K
House · CA · Jun 8, 2026
Buy$1K-$15K
House · CA · May 6, 2025
Buy$1K-$15K
House · CA · May 6, 2025
Buy$1K-$15K